DK1456377T3 - Syn3-sammensætninger og fremgangsmåder - Google Patents
Syn3-sammensætninger og fremgangsmåder Download PDFInfo
- Publication number
- DK1456377T3 DK1456377T3 DK02805671.1T DK02805671T DK1456377T3 DK 1456377 T3 DK1456377 T3 DK 1456377T3 DK 02805671 T DK02805671 T DK 02805671T DK 1456377 T3 DK1456377 T3 DK 1456377T3
- Authority
- DK
- Denmark
- Prior art keywords
- syn3
- procedures
- compositions
- syn3 compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34232901P | 2001-12-20 | 2001-12-20 | |
PCT/US2002/041198 WO2003053365A2 (en) | 2001-12-20 | 2002-12-20 | Syn3 compositions and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1456377T3 true DK1456377T3 (da) | 2019-09-23 |
Family
ID=23341353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02805671.1T DK1456377T3 (da) | 2001-12-20 | 2002-12-20 | Syn3-sammensætninger og fremgangsmåder |
Country Status (13)
Country | Link |
---|---|
US (3) | US20030170216A1 (da) |
EP (1) | EP1456377B1 (da) |
JP (2) | JP4727923B2 (da) |
AU (1) | AU2002366809A1 (da) |
CA (1) | CA2470999C (da) |
CY (1) | CY1121982T1 (da) |
DK (1) | DK1456377T3 (da) |
ES (1) | ES2745068T3 (da) |
MX (1) | MXPA04005942A (da) |
PT (1) | PT1456377T (da) |
SI (1) | SI1456377T1 (da) |
TR (1) | TR201910060T4 (da) |
WO (1) | WO2003053365A2 (da) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040014709A1 (en) * | 1996-01-08 | 2004-01-22 | Canji, Inc. | Methods and compositions for interferon therapy |
US6392069B2 (en) * | 1996-01-08 | 2002-05-21 | Canji, Inc. | Compositions for enhancing delivery of nucleic acids to cells |
US7002027B1 (en) * | 1996-01-08 | 2006-02-21 | Canji, Inc. | Compositions and methods for therapeutic use |
US5789244A (en) * | 1996-01-08 | 1998-08-04 | Canji, Inc. | Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems |
CN101396555A (zh) * | 2003-06-04 | 2009-04-01 | 坎基股份有限公司 | 用于干扰素治疗的方法和组合物 |
JP4801594B2 (ja) | 2003-12-10 | 2011-10-26 | カンジ,インコーポレイテッド | インターフェロン耐性腫瘍の処置のための方法および組成物 |
EP3046536B1 (en) | 2013-09-19 | 2018-11-28 | Janssen Vaccines & Prevention B.V. | Improved adenovirus formulations |
EP3442588A4 (en) * | 2016-04-14 | 2020-02-19 | Trizell Ltd. | VIRAL VECTOR STABILIZATION |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7105156B1 (en) * | 1987-09-17 | 2006-09-12 | The Regents Of The University Of California | Method of using an adenoviral vector encoding a retinoblastoma protein to treat hyperproliferating cells |
US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
ES2096614T3 (es) * | 1990-12-06 | 1997-03-16 | Hoechst Ag | Derivados de acidos biliares, procedimiento para su preparacion y utilizacion de este compuesto como medicamento. |
US6013638A (en) * | 1991-10-02 | 2000-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung |
US5795870A (en) | 1991-12-13 | 1998-08-18 | Trustees Of Princeton University | Compositions and methods for cell transformation |
ES2189808T3 (es) | 1993-10-15 | 2003-07-16 | Cytrx Corp | Composiciones de aporte terapeutico y metodos de uso de las mismas. |
US6210939B1 (en) | 1993-10-25 | 2001-04-03 | Canji, Inc. | Recombinant adenoviral vector and methods of use |
US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
US5552309A (en) * | 1994-09-30 | 1996-09-03 | Indiana University Foundation | Use of polyols for improving the introduction of genetic material into cells |
US7002027B1 (en) * | 1996-01-08 | 2006-02-21 | Canji, Inc. | Compositions and methods for therapeutic use |
US20040014709A1 (en) * | 1996-01-08 | 2004-01-22 | Canji, Inc. | Methods and compositions for interferon therapy |
US6392069B2 (en) * | 1996-01-08 | 2002-05-21 | Canji, Inc. | Compositions for enhancing delivery of nucleic acids to cells |
US5789244A (en) | 1996-01-08 | 1998-08-04 | Canji, Inc. | Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems |
ES2234018T3 (es) * | 1996-04-26 | 2005-06-16 | MERCK & CO., INC. | Formulaciones de vacunas de adn. |
US6133248A (en) * | 1997-06-13 | 2000-10-17 | Cydex, Inc. | Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof |
DE19734860C2 (de) * | 1997-08-12 | 1999-12-16 | Bosch Gmbh Robert | Verfahren zur Bestimmung oxidierbarer Bestandteile in einem Gasgemisch |
CN100471522C (zh) * | 1998-03-13 | 2009-03-25 | 惠氏 | 聚核苷酸组合物及其制备方法与用途 |
US6166779A (en) * | 1999-04-27 | 2000-12-26 | Nucore Technology Inc. | Method for analog decimation of image signals |
EP1074248A1 (en) * | 1999-07-08 | 2001-02-07 | Arnold Hilgers | Delivery system for biological material |
WO2004108898A2 (en) | 2003-06-04 | 2004-12-16 | Canji, Inc. | Transfection agents |
WO2004108088A2 (en) * | 2003-06-04 | 2004-12-16 | Canji, Inc. | Methods and compositions for interferon therapy |
CN101396555A (zh) * | 2003-06-04 | 2009-04-01 | 坎基股份有限公司 | 用于干扰素治疗的方法和组合物 |
JP4801594B2 (ja) * | 2003-12-10 | 2011-10-26 | カンジ,インコーポレイテッド | インターフェロン耐性腫瘍の処置のための方法および組成物 |
JP2008203500A (ja) * | 2007-02-20 | 2008-09-04 | Fuji Xerox Co Ltd | ホログラム記録材料、ホログラム記録媒体、および、ホログラム記録方法 |
-
2002
- 2002-12-20 PT PT02805671T patent/PT1456377T/pt unknown
- 2002-12-20 US US10/329,043 patent/US20030170216A1/en not_active Abandoned
- 2002-12-20 JP JP2003554125A patent/JP4727923B2/ja not_active Expired - Lifetime
- 2002-12-20 TR TR2019/10060T patent/TR201910060T4/tr unknown
- 2002-12-20 CA CA2470999A patent/CA2470999C/en not_active Expired - Lifetime
- 2002-12-20 ES ES02805671T patent/ES2745068T3/es not_active Expired - Lifetime
- 2002-12-20 SI SI200231095T patent/SI1456377T1/sl unknown
- 2002-12-20 EP EP02805671.1A patent/EP1456377B1/en not_active Expired - Lifetime
- 2002-12-20 DK DK02805671.1T patent/DK1456377T3/da active
- 2002-12-20 MX MXPA04005942A patent/MXPA04005942A/es not_active Application Discontinuation
- 2002-12-20 WO PCT/US2002/041198 patent/WO2003053365A2/en active Application Filing
- 2002-12-20 AU AU2002366809A patent/AU2002366809A1/en not_active Abandoned
-
2010
- 2010-02-03 JP JP2010022598A patent/JP2010095549A/ja not_active Withdrawn
- 2010-07-19 US US12/838,795 patent/US9115374B2/en not_active Expired - Fee Related
-
2015
- 2015-07-13 US US14/798,277 patent/US20150313926A1/en not_active Abandoned
-
2019
- 2019-09-03 CY CY20191100923T patent/CY1121982T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
US20150313926A1 (en) | 2015-11-05 |
US9115374B2 (en) | 2015-08-25 |
CA2470999A1 (en) | 2003-07-03 |
JP2010095549A (ja) | 2010-04-30 |
ES2745068T3 (es) | 2020-02-27 |
AU2002366809A8 (en) | 2003-07-09 |
WO2003053365A3 (en) | 2003-10-30 |
WO2003053365A2 (en) | 2003-07-03 |
JP4727923B2 (ja) | 2011-07-20 |
PT1456377T (pt) | 2019-09-10 |
EP1456377A2 (en) | 2004-09-15 |
MXPA04005942A (es) | 2005-05-16 |
US20030170216A1 (en) | 2003-09-11 |
CY1121982T1 (el) | 2020-10-14 |
SI1456377T1 (sl) | 2019-09-30 |
CA2470999C (en) | 2017-02-21 |
EP1456377A4 (en) | 2010-07-07 |
TR201910060T4 (tr) | 2019-07-22 |
AU2002366809A1 (en) | 2003-07-09 |
EP1456377B1 (en) | 2019-06-12 |
JP2005513086A (ja) | 2005-05-12 |
US20100324126A1 (en) | 2010-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1202941T3 (da) | Gipssammensætninger og beslægtede fremgangsmåder | |
DK1417175T3 (da) | Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf | |
DK1242095T3 (da) | Antimikrobielle sammensætninger og fremgangsmåder til anvendelse deraf | |
NO20000011D0 (no) | Skumdempersammensetninger og fremgangsmåter | |
IS6934A (is) | Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar | |
DK1329456T3 (da) | Glucopyranosyloxybenzylbenzenderivater og medicinske sammensætninger indeholdende samme | |
NO20000847L (no) | Elastiske brønnsementsammensetninger og fremgangsmÕter | |
DK1370128T3 (da) | Kombineret ballepresse og ballevikler | |
AU2002357119A8 (en) | Mitocidal compositions and methods | |
NO20013393D0 (no) | Brönnsementeringsfremgangsmåter og sammensetninger | |
DE60317699D1 (de) | Fermentationsverfahren und -zusammensetzungen | |
NO20005828L (no) | Herdbare punktfluidsammensetninger og fremgangsmåter | |
DK1404809T3 (da) | Forbedrede hudsubstitutter og anvendelser deraf | |
DK1339292T3 (da) | Sammensætning og fremgangsmåde | |
NO20021786L (no) | Skumdempningsfremgangsmåter og sammensetninger | |
NO20034159L (no) | Östrogen-gestagen-kombinasjonspreparat og anvendelse derav | |
DK1429769T3 (da) | Nye formuleringer og anvendelse deraf | |
NO20033854L (no) | N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse | |
IS2841B (is) | Samstæða hluta og lyfjasamsetningar | |
DK1601744T3 (da) | Forgasningsapparat og fremgangsmåde | |
EP1455841A4 (en) | OSTEOPONTIN-RELATED COMPOSITIONS AND METHODS | |
IS7275A (is) | Samsetning fyrir hollegg og notkun á henni | |
DK1456377T3 (da) | Syn3-sammensætninger og fremgangsmåder | |
NO20042047L (no) | Forseglingssammensetning og dens anvendelse | |
NO20030156D0 (no) | Farmasöytiske sammensetninger og fremgangsmåter for anvendelse derav |